(Q37162808)

18 August 2017

1 reference

title

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia (English)

1 reference

18 August 2017

0 references

0 references

1 reference

Veronica O'Keane

1

0 references

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Journal of Psychopharmacology

18 August 2017

1 reference

18 August 2017

22

1 reference

18 August 2017

2 Suppl

1 reference

18 August 2017

70-75

1 reference

Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study

18 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Prolactin and dopamine: what is the connection? A review article

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Sex hormones in psychotic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

The impact of hyperprolactinaemia on sexual function in patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881107088439

21 January 2018

Identifiers

DOI

10.1177/0269881107088439

1 reference

18 August 2017

1 reference

PubMed ID

18477623